AbbVie Inc. (ABBV) — closed signal from November 13, 2025
Partial Published before the outcome was known, scored automatically when the window closed on February 11, 2026.
Predicted vs. what happened
What happened
Reached 10% of the predicted growth at its peak, without hitting the target.
The thesis — published November 13, 2025
AbbVie's uptrend looks back on track. Recent buying pressure is strong, and the recent average price is still rising, but it may be smarter to consider buys on down days rather than chasing jumps. Attention on big healthcare names is high after the Dow hit a record, which helps. Over the next 0-3 months, its dividend and drug pipeline can keep the move going, but shifting markets call for patient entries and adds after strong closes.
Primary drivers
- Buying pressure is strong and the recent average price is still rising
- Investor mood is positive, and the steady dividend helps anchor demand
- Investors are closely focused on the stock, keeping interest high
- Buy on down days to manage shifts between market sectors and reduce risk
How it played out
ABBV: target was not reached
Lyra published ABBV on 2025-11-13 at 236.87 with expected growth of 10%. The thesis pointed to strong buying pressure, a still-rising recent average price, positive investor mood, steady dividend support, close investor focus on the stock, and patient entries on down days.
Inside the window from 2025-11-13 to 2026-02-11, ABBV peaked at 239.29 on 2025-11-13, with a peak gain of 1%. It stayed below the 260.55 target. The stock ended at 220.89. The published thesis missed.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.